Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEPEZZA in Chronic (Inactive) Thyroid Eye Disease
NCT04583735Phase 4Completed
- Sponsor
- Amgen
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in thyroid eye disease (TED) comparing TEPEZZA with Placebo (2 arms). Primary endpoint: Change From Baseline in Proptosis of Study Eye at Week 24. Started Sep 2021; status: completed.
02
Drugs
teprotumumab
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT04583735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04583735.